GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option

The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for pre-exposure prophylaxis (PrEP).
The priority review designation sets ViiV up for a decision from the agency by January 24, 2022.
If approved, it'd be the first long-acting PrEP drug and would challenge medicines from Gilead Sciences Inc GILD.
ViiV Healthcare is a joint venture between GlaxoSmithKline plc GSK, Pfizer Inc PFE, and Shionogi.
ViiV Healthcare will initiate submissions of cabotegravir long-acting for PrEP to other regulatory authorities by the end of 2021
Related content: Benzinga's Full FDA Calendar.
Price Action: PFE stock is down 1.77% at $42.80, and GSK stock is down 0.94% at $38.14 during the market session on the last check Tuesday.

Overview Rating:

Good

100

0100